

Immune Checkpoint Inhibitors Market by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Application (Lung Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Hodgkin Lymphoma, and Others), and Region 2023-2028

<https://marketpublishers.com/r/l6519EE1999DEN.html>

Date: March 2023

Pages: 143

Price: US\$ 2,499.00 (Single User License)

ID: I6519EE1999DEN

Abstracts

Market Overview:

The global immune checkpoint inhibitors market size reached US\$ 36.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US\$ 97.3 Billion by 2028, exhibiting a growth rate (CAGR) of 17.19% during 2023-2028. The rising prevalence of various cancers, increasing incidences of respiratory disorders, and the growing preference for personalized medicines represent some of the key factors driving the market.

Immune checkpoint inhibitors are drugs utilized for treating cancer by inhibiting specific proteins made by immune system cells, such as T cells and cancer cells. They are either used alone or in combination with other cancer treatments, such as chemotherapy and radiation therapy to enhance treatment outcomes. They aid in enhancing the quality of life for cancer patients by reducing the symptoms of the disease and extending their survival. Immune checkpoint inhibitors target specific pathways in the immune system, which enables a more targeted approach to cancer treatment. These inhibitors have a lower toxicity profile that leads to fewer side effects and better tolerance to patients as compared to traditional chemotherapy. At present, the rising use of next-generation sequencing technologies that enables the identification

of specific genetic mutations in cancer cells is catalyzing the demand for immune checkpoint inhibitors across the globe.

Immune Checkpoint Inhibitors Market Trends:

The surging prevalence of various cancers among individuals, such as melanoma, liver, kidney, and gastric, represents one of the major factors driving the demand for immune checkpoint inhibitors around the world. Moreover, the increasing aging population, which is more prone to develop such severe cancers and the rising prevalence of obesity is favoring the market growth. In addition, there is an increase in the incidences of respiratory disorders on account of the rising consumption of alcoholic beverages and tobacco-based products. This, coupled with the growing numbers of weight-related health concerns on account of unhealthy eating habits and sedentary lifestyles, is influencing the market positively. Apart from this, the surging occurrence of various genetic and lifestyle diseases and the increasing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of cancer is propelling the growth of the market. Furthermore, the expanding number of clinical trials by pharmaceutical companies and the rising preference for personalized medicines and new generation drugs and formulations are propelling the growth of the market. Besides this, the growing focus of leading players on strategic collaborations and new product developments to expand their product portfolio and gain a competitive edge is creating a positive outlook for the market. Additionally, significant improvements in medical infrastructure and diagnostic technologies are anticipated to strengthen the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global immune checkpoint inhibitors market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on type, distribution channel, and application.

Type Insights:

CTLA-4 Inhibitor

PD-1 Inhibitor

PD-L1 Inhibitor

The report has provided a detailed breakup and analysis of the immune checkpoint inhibitors market based on the type. This includes CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. According to the report, PD-1 inhibitor represented the largest segment.

Distribution Channel Insights:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

A detailed breakup and analysis of the immune checkpoint inhibitors market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Application Insights:

Lung Cancer

Bladder Cancer

Melanoma

Colorectal Cancer

Hodgkin Lymphoma

Others

The report has provided a detailed breakup and analysis of the immune checkpoint inhibitors market based on the application. This includes lung cancer, bladder cancer, melanoma, colorectal cancer, Hodgkin lymphoma, and others. According to the report, lung cancer represented the largest segment.

Regional Insights:

North America

United States

Canada

Asia Pacific

China
Japan
India
South Korea
Australia
Indonesia
Others

Europe

Germany
France
United Kingdom
Italy
Spain
Russia
Others

Latin America

Brazil
Mexico
Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for immune checkpoint inhibitors. Some of the factors driving the North America immune checkpoint inhibitors market included the increasing aging population, presence of a well-established healthcare infrastructure, rising research and development (R&D) activities, etc.

Competitive Landscape:

Immune Checkpoint Inhibitors Market by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor), Distribution...

The report has also provided a comprehensive analysis of the competitive landscape in the global immune checkpoint inhibitors market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Seagen Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

How has the global immune checkpoint inhibitors market performed so far, and how will it perform in the coming years?

What are the drivers, restraints, and opportunities in the global immune checkpoint inhibitors market?

What is the impact of each driver, restraint, and opportunity on the global immune checkpoint inhibitors market?

What are the key regional markets?

Which countries represent the most attractive immune checkpoint inhibitors market?

What is the breakup of the market based on the type?

Which is the most attractive type in the immune checkpoint inhibitors market?

What is the breakup of the market based on the distribution channel?

Which is the most attractive distribution channel in the immune checkpoint inhibitors market?

What is the breakup of the market based on application?

Which is the most attractive application in the immune checkpoint inhibitors market?

What is the competitive structure of the global immune checkpoint inhibitors market?

Who are the key players/companies in the global immune checkpoint inhibitors market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 INTRODUCTION

- 4.1 Overview
- 4.2 Key Industry Trends

5 GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET

- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast

6 MARKET BREAKUP BY TYPE

- 6.1 CTLA-4 Inhibitor
 - 6.1.1 Market Trends
 - 6.1.2 Market Forecast
- 6.2 PD-1 Inhibitor
 - 6.2.1 Market Trends
 - 6.2.2 Market Forecast
- 6.3 PD-L1 Inhibitor

- 6.3.1 Market Trends
- 6.3.2 Market Forecast

7 MARKET BREAKUP BY DISTRIBUTION CHANNEL

- 7.1 Hospital Pharmacies
 - 7.1.1 Market Trends
 - 7.1.2 Market Forecast
- 7.2 Retail Pharmacies
 - 7.2.1 Market Trends
 - 7.2.2 Market Forecast
- 7.3 Online Pharmacies
 - 7.3.1 Market Trends
 - 7.3.2 Market Forecast

8 MARKET BREAKUP BY APPLICATION

- 8.1 Lung Cancer
 - 8.1.1 Market Trends
 - 8.1.2 Market Forecast
- 8.2 Bladder Cancer
 - 8.2.1 Market Trends
 - 8.2.2 Market Forecast
- 8.3 Melanoma
 - 8.3.1 Market Trends
 - 8.3.2 Market Forecast
- 8.4 Colorectal Cancer
 - 8.4.1 Market Trends
 - 8.4.2 Market Forecast
- 8.5 Hodgkin Lymphoma
 - 8.5.1 Market Trends
 - 8.5.2 Market Forecast
- 8.6 Others
 - 8.6.1 Market Trends
 - 8.6.2 Market Forecast

9 MARKET BREAKUP BY REGION

- 9.1 North America

- 9.1.1 United States
 - 9.1.1.1 Market Trends
 - 9.1.1.2 Market Forecast
- 9.1.2 Canada
 - 9.1.2.1 Market Trends
 - 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
 - 9.2.1 China
 - 9.2.1.1 Market Trends
 - 9.2.1.2 Market Forecast
 - 9.2.2 Japan
 - 9.2.2.1 Market Trends
 - 9.2.2.2 Market Forecast
 - 9.2.3 India
 - 9.2.3.1 Market Trends
 - 9.2.3.2 Market Forecast
 - 9.2.4 South Korea
 - 9.2.4.1 Market Trends
 - 9.2.4.2 Market Forecast
 - 9.2.5 Australia
 - 9.2.5.1 Market Trends
 - 9.2.5.2 Market Forecast
 - 9.2.6 Indonesia
 - 9.2.6.1 Market Trends
 - 9.2.6.2 Market Forecast
 - 9.2.7 Others
 - 9.2.7.1 Market Trends
 - 9.2.7.2 Market Forecast
- 9.3 Europe
 - 9.3.1 Germany
 - 9.3.1.1 Market Trends
 - 9.3.1.2 Market Forecast
 - 9.3.2 France
 - 9.3.2.1 Market Trends
 - 9.3.2.2 Market Forecast
 - 9.3.3 United Kingdom
 - 9.3.3.1 Market Trends
 - 9.3.3.2 Market Forecast
 - 9.3.4 Italy

- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
 - 9.3.5.1 Market Trends
 - 9.3.5.2 Market Forecast
- 9.3.6 Russia
 - 9.3.6.1 Market Trends
 - 9.3.6.2 Market Forecast
- 9.3.7 Others
 - 9.3.7.1 Market Trends
 - 9.3.7.2 Market Forecast
- 9.4 Latin America
 - 9.4.1 Brazil
 - 9.4.1.1 Market Trends
 - 9.4.1.2 Market Forecast
 - 9.4.2 Mexico
 - 9.4.2.1 Market Trends
 - 9.4.2.2 Market Forecast
 - 9.4.3 Others
 - 9.4.3.1 Market Trends
 - 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
 - 9.5.1 Market Trends
 - 9.5.2 Market Breakup by Country
 - 9.5.3 Market Forecast

10 DRIVERS, RESTRAINTS, AND OPPORTUNITIES

- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities

11 VALUE CHAIN ANALYSIS

12 PORTERS FIVE FORCES ANALYSIS

- 12.1 Overview
- 12.2 Bargaining Power of Buyers

- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes

13 PRICE ANALYSIS

14 COMPETITIVE LANDSCAPE

- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
 - 14.3.1 AstraZeneca plc
 - 14.3.1.1 Company Overview
 - 14.3.1.2 Product Portfolio
 - 14.3.1.3 Financials
 - 14.3.1.4 SWOT Analysis
 - 14.3.2 Bristol-Myers Squibb Company
 - 14.3.2.1 Company Overview
 - 14.3.2.2 Product Portfolio
 - 14.3.2.3 Financials
 - 14.3.2.4 SWOT Analysis
 - 14.3.3 GSK plc
 - 14.3.3.1 Company Overview
 - 14.3.3.2 Product Portfolio
 - 14.3.3.3 Financials
 - 14.3.3.4 SWOT Analysis
 - 14.3.4 Merck & Co. Inc.
 - 14.3.4.1 Company Overview
 - 14.3.4.2 Product Portfolio
 - 14.3.4.3 Financials
 - 14.3.4.4 SWOT Analysis
 - 14.3.5 Ono Pharmaceutical Co. Ltd.
 - 14.3.5.1 Company Overview
 - 14.3.5.2 Product Portfolio
 - 14.3.5.3 Financials
 - 14.3.5.4 SWOT Analysis
 - 14.3.6 Pfizer Inc.
 - 14.3.6.1 Company Overview

14.3.6.2 Product Portfolio

14.3.6.3 Financials

14.3.6.4 SWOT Analysis

14.3.7 Regeneron Pharmaceuticals Inc.

14.3.7.1 Company Overview

14.3.7.2 Product Portfolio

14.3.7.3 Financials

14.3.7.4 SWOT Analysis

14.3.8 Seagen Inc.

14.3.8.1 Company Overview

14.3.8.2 Product Portfolio

14.3.8.3 Financials

14.3.8.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List Of Tables

LIST OF TABLES

Table 1: Global: Immune Checkpoint Inhibitors Market: Key Industry Highlights, 2022 & 2028

Table 2: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Type (in Million US\$), 2023-2028

Table 3: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Distribution Channel (in Million US\$), 2023-2028

Table 4: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Application (in Million US\$), 2023-2028

Table 5: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Region (in Million US\$), 2023-2028

Table 6: Global: Immune Checkpoint Inhibitors Market: Competitive Structure

Table 7: Global: Immune Checkpoint Inhibitors Market: Key Players

List Of Figures

LIST OF FIGURES

Figure 1: Global: Immune Checkpoint Inhibitors Market: Major Drivers and Challenges

Figure 2: Global: Immune Checkpoint Inhibitors Market: Sales Value (in Billion US\$), 2017-2022

Figure 3: Global: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Billion US\$), 2023-2028

Figure 4: Global: Immune Checkpoint Inhibitors Market: Breakup by Type (in %), 2022

Figure 5: Global: Immune Checkpoint Inhibitors Market: Breakup by Distribution Channel (in %), 2022

Figure 6: Global: Immune Checkpoint Inhibitors Market: Breakup by Application (in %), 2022

Figure 7: Global: Immune Checkpoint Inhibitors Market: Breakup by Region (in %), 2022

Figure 8: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 9: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 10: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 11: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 12: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 13: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 14: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 15: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 16: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 17: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 18: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 19: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 20: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 21: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 22: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 23: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 24: Global: Immune Checkpoint Inhibitors (Melanoma) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 25: Global: Immune Checkpoint Inhibitors (Melanoma) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 26: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 27: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 28: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 29: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 30: Global: Immune Checkpoint Inhibitors (Other Applications) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 31: Global: Immune Checkpoint Inhibitors (Other Applications) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 32: North America: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 33: North America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 34: United States: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 35: United States: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 36: Canada: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 37: Canada: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 38: Asia-Pacific: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 39: Asia-Pacific: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in

Million US\$), 2023-2028

Figure 40: China: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 41: China: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 42: Japan: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 43: Japan: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 44: India: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 45: India: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 46: South Korea: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 47: South Korea: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 48: Australia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 49: Australia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 50: Indonesia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 51: Indonesia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 52: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 53: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 54: Europe: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 55: Europe: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 56: Germany: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 57: Germany: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 58: France: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 59: France: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 60: United Kingdom: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 61: United Kingdom: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 62: Italy: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 63: Italy: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 64: Spain: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 65: Spain: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 66: Russia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 67: Russia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 68: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 69: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 70: Latin America: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 71: Latin America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 72: Brazil: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 73: Brazil: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 74: Mexico: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 75: Mexico: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 76: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US\$), 2017 & 2022

Figure 77: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 78: Middle East and Africa: Immune Checkpoint Inhibitors Market: Sales Value

(in Million US\$), 2017 & 2022

Figure 79: Middle East and Africa: Immune Checkpoint Inhibitors Market: Breakup by Country (in %), 2022

Figure 80: Middle East and Africa: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 81: Global: Immune Checkpoint Inhibitors Industry: Drivers, Restraints, and Opportunities

Figure 82: Global: Immune Checkpoint Inhibitors Industry: Value Chain Analysis

Figure 83: Global: Immune Checkpoint Inhibitors Industry: Porter's Five Forces Analysis

I would like to order

Product name: Immune Checkpoint Inhibitors Market by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Application (Lung Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Hodgkin Lymphoma, and Others), and Region 2023-2028

Product link: <https://marketpublishers.com/r/I6519EE1999DEN.html>

Price: US\$ 2,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I6519EE1999DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970